November 2025 in “Frontiers in Immunology” Immune cells are crucial for normal skin development and their dysfunction can cause skin disorders.
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
March 2024 in “Research Square” The model helps understand alopecia areata and suggests ways to improve treatment by targeting immune issues.
January 2024 in “Research Square” The model helps understand alopecia areata and suggests treatment strategies.
January 2024 in “Applied Mathematics and Nonlinear Sciences” The model helps understand alopecia areata and suggests better treatment strategies.
June 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” ILC1-like cells can cause alopecia areata by attacking hair follicles.
March 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” A specific immune response helps control mite populations on the skin, maintaining healthy hair follicles.
Lichen planopilaris and frontal fibrosing alopecia are likely the same disease with different clinical appearances.
33 citations
,
October 2006 in “European Journal of Immunology” The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
17 citations
,
January 2010 in “PubMed” CD10 helps distinguish between basal cell carcinoma and benign hair follicle tumors.
July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
5 citations
,
November 2005 in “Journal of Investigative Dermatology” 30 citations
,
April 2007 in “Journal of Leukocyte Biology” Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
141 citations
,
May 2007 in “Cancer Research” CD34 is crucial for skin tumor development in mice.
The CD4 protein may play a role in the behavior of certain skin cells, affecting their growth, movement, and differentiation.
6 citations
,
April 2017 in “Experimental dermatology” CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
May 2026 in “Chemical Engineering Journal”
3 citations
,
April 2010 in “The American Journal of Dermatopathology” Most people with scarring and nonscarring hair loss show similar D2-40 levels, but some with scarring hair loss have higher levels.
21 citations
,
July 2006 in “Veterinary dermatology” CD34 marks potential stem cells in dog hair follicles.
DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.
2 citations
,
May 2024 in “International Journal of Molecular Sciences” Targeting CD169+ skin macrophages may help treat psoriasis.
May 2024 in “International journal of medicine and psychology.” Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.
8 citations
,
August 2025 in “Journal of Translational Medicine” CD44 signaling can help heal wounds without scars.
28 citations
,
April 2024 in “Immunity” CD80 on skin stem cells helps expand Treg cells to aid wound healing.
522 citations
,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.